PCI Biotech announced that results from preclinical studies on tuberculosis performed in collaboration with The University of Zurich and ETH Zurich are accepted for publication in Frontiers in Immunology, a high impact immunology journal. The article title is 'Photochemically-mediated inflammation and cross-presentation of Mycobacterium bovis BCG proteins stimulates strong CD4 and CD8 T-cell responses in mice'.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.858 NOK | -2.21% | -2.21% | -11.31% |
1st Jan change | Capi. | |
---|---|---|
-11.31% | 6.64M | |
+16.49% | 122B | |
+21.73% | 115B | |
+22.97% | 26.64B | |
-21.81% | 19.91B | |
-16.87% | 16.32B | |
-18.81% | 15.49B | |
-44.74% | 15.52B | |
+62.72% | 14.83B | |
+3.09% | 13.67B |
- Stock Market
- Equities
- PCIB Stock
- News PCI Biotech Holding ASA
- PCI Biotech Announces Publication of Preclinical Tuberculosis Results